Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is...
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is...
First off, please don't take anything I been saying seriously or as financial advice. As always, this is on an opinion based basis. That being said XCUR has a reasonable target of reaching $3.30 soon in my opinion. It is still on a positive retracement wave looking at the entire chart history, and the bullish run looks to be continuing. The only reason I would...
Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered...
Welcome Hyperspace Archaeologists,
Come for the laughs, stay for the Art.
___________________
Find the "we are here" bubble.
I am most likely wrong...
Meh . Who cares.
but what... if..
good enough for me! All in. #pewpeww
__________________________________
Trade Taken:
Entry Range is $2.38 - $2.45
Target $8.60
Hold until April 2021
Technical.
One Cajun Ship...
